Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) EBT Margin (2017 - 2025)

Historic EBT Margin for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to 519.23%.

  • Arcus Biosciences' EBT Margin fell 3275600.0% to 519.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 141.67%, marking a year-over-year decrease of 393900.0%. This contributed to the annual value of 109.3% for FY2024, which is 1479600.0% up from last year.
  • As of Q3 2025, Arcus Biosciences' EBT Margin stood at 519.23%, which was down 3275600.0% from 400.0% recorded in Q1 2025.
  • In the past 5 years, Arcus Biosciences' EBT Margin registered a high of 79.39% during Q4 2021, and its lowest value of 824.17% during Q3 2021.
  • Moreover, its 5-year median value for EBT Margin was 256.62% (2023), whereas its average is 337.78%.
  • The largest annual percentage gain for Arcus Biosciences' EBT Margin in the last 5 years was 17726800bps (2021), contrasted with its biggest fall of -8270000bps (2021).
  • Over the past 5 years, Arcus Biosciences' EBT Margin (Quarter) stood at 79.39% in 2021, then plummeted by -348bps to 197.06% in 2022, then tumbled by -31bps to 258.06% in 2023, then tumbled by -39bps to 357.69% in 2024, then crashed by -45bps to 519.23% in 2025.
  • Its EBT Margin stands at 519.23% for Q3 2025, versus 400.0% for Q1 2025 and 357.69% for Q4 2024.